| Time | Session |
|---|---|
|
3 p.m.
3:10 p.m.
|
Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
|
|
3:10 p.m.
3:25 p.m.
|
Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas – Recommendations and Updates
Wladimir MietekSzpirt
Speaker
wladimir.mietek.szpirt.01@regionh.dkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research ConsultantDenmark
|
|
3:25 p.m.
3:35 p.m.
|
EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
|
|
3:35 p.m.
3:45 p.m.
|
SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
JonathanBarratt
Free Communication
jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
|
|
3:45 p.m.
3:55 p.m.
|
PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
CécileCouchoud
Free Communication
cecile.couchoud@biomedecine.frREIN registry, Agence de la biomédecine, FranceFrance
|